Lv1
4 积分 2023-06-30 加入
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
2小时前
已完结
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
2小时前
已完结
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
2小时前
已完结
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
2小时前
已完结
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
2小时前
已完结
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study
2小时前
已完结
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
2小时前
已完结
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer
2小时前
已完结
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
3小时前
已完结
The dawn of immunotherapy in mismatch repair proficient colorectal cancer
4天前
已完结
皖公网安备34019202002308
